Monitoring panel recommends SER-252 trial advance to second dosing group
Written by Andrea Lobo | Sept. 21, 2026
- SER-252, a long-acting apomorphine therapy delivered via a wearable device, eased motor symptoms in some trial patients with advanced Parkinson's.
- A safety panel recommended the Phase 1b trial advance to a second dosing group.
- The trial is enrolling patients at sites in the U.S. and Australia.
A Parkinson’s disease therapy delivered through a wearable device eased motor function in some patients with advanced Parkinson’s, according to preliminary observations from an ongoing Phase 1b trial.
An independent safety monitoring committee recommended that the trial of SER-252, Serina Therapeutics’ long-acting form of apomorphine, advance to a second dosing group. The panel reviewed safety and tolerability data from the first eight patients, who received the lowest dose of the drug. This dose provided the sustained exposure to apomorphine that the treatment aims to deliver.
“These initial observations strengthen our confidence in SER-252 and are consistent with the profile the program was designed to achieve,” Steve Ledger, Serina’s CEO, said in a company press release.
The Phase 1b trial (NCT07422675) is still enrolling patients at sites in the U.S. and Australia. The company expects to report top-line data in the first half of 2027.
Parkinson’s disease develops as dopaminergic neurons, the nerve cells that produce dopamine, gradually die. Dopamine is important for controlling movement, and its loss contributes to motor symptoms such as tremor, stiffness, and slowed movement.
Recommended Reading
Recent Comments